Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.

2.50
Hdl Handle:
http://hdl.handle.net/10541/77869
Title:
Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.
Authors:
Wells, Paula; West, Catharine M L; Jones, Terry; Harris, Adrian L; Price, Patricia M
Abstract:
[(18)F]-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) is becoming accepted as a diagnostic tool for cancer, but the potential uses of PET in oncology extend beyond the imaging of glucose metabolism. The development of a PET proliferation probe would be a useful pharmacodynamic tool. [(11)C]-thymidine PET has been assessed in man as a specific measure of tumor proliferation. Uptake of [(11)C]-thymidine is related to DNA synthesis and, in human tumors, correlates with proliferation. When compared with (18)F-FDG, it has been shown to be a more sensitive discriminator of early clinical tumor response. 2-[(11)C]-thymidine PET scanning of patients enrolled in early phase clinical trials is feasible and should support future drug development. Although recent research is moving away from the validation of thymidine towards thymidine analogues radiolabeled with (18)F, the better specificity of thymidine for DNA should be the rationale for its continued development and application as a PET probe. This review describes the historical development, application and current research status of [(11)C]-thymidine PET, and aims to highlight the need for its continuing development as a marker of tumor proliferation.
Affiliation:
Department of Radiotherapy, St. Bartholomews' Hospital, West Smithfield, London EC1A 7BE, UK.
Citation:
Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. 2004, 1705 (2):91-102 Biochim. Biophys. Acta
Journal:
Biochimica et Biophysica Acta
Issue Date:
17-Dec-2004
URI:
http://hdl.handle.net/10541/77869
DOI:
10.1016/j.bbcan.2004.09.007
PubMed ID:
15588764
Type:
Article
Language:
en
ISSN:
0006-3002
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorWells, Paula-
dc.contributor.authorWest, Catharine M L-
dc.contributor.authorJones, Terry-
dc.contributor.authorHarris, Adrian L-
dc.contributor.authorPrice, Patricia M-
dc.date.accessioned2009-08-19T14:23:53Z-
dc.date.available2009-08-19T14:23:53Z-
dc.date.issued2004-12-17-
dc.identifier.citationMeasuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine. 2004, 1705 (2):91-102 Biochim. Biophys. Actaen
dc.identifier.issn0006-3002-
dc.identifier.pmid15588764-
dc.identifier.doi10.1016/j.bbcan.2004.09.007-
dc.identifier.urihttp://hdl.handle.net/10541/77869-
dc.description.abstract[(18)F]-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) is becoming accepted as a diagnostic tool for cancer, but the potential uses of PET in oncology extend beyond the imaging of glucose metabolism. The development of a PET proliferation probe would be a useful pharmacodynamic tool. [(11)C]-thymidine PET has been assessed in man as a specific measure of tumor proliferation. Uptake of [(11)C]-thymidine is related to DNA synthesis and, in human tumors, correlates with proliferation. When compared with (18)F-FDG, it has been shown to be a more sensitive discriminator of early clinical tumor response. 2-[(11)C]-thymidine PET scanning of patients enrolled in early phase clinical trials is feasible and should support future drug development. Although recent research is moving away from the validation of thymidine towards thymidine analogues radiolabeled with (18)F, the better specificity of thymidine for DNA should be the rationale for its continued development and application as a PET probe. This review describes the historical development, application and current research status of [(11)C]-thymidine PET, and aims to highlight the need for its continuing development as a marker of tumor proliferation.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshCarbon Radioisotopes-
dc.subject.meshCell Proliferation-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshDNA Probes-
dc.subject.meshFluorodeoxyglucose F18-
dc.subject.meshHumans-
dc.subject.meshNeoplasms-
dc.subject.meshPositron-Emission Tomography-
dc.subject.meshReproducibility of Results-
dc.subject.meshThymidine-
dc.titleMeasuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.en
dc.typeArticleen
dc.contributor.departmentDepartment of Radiotherapy, St. Bartholomews' Hospital, West Smithfield, London EC1A 7BE, UK.en
dc.identifier.journalBiochimica et Biophysica Actaen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.